Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.

NCT04621422 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT04621422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04621422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2020
Completion date
January 31, 2023
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuro-degenerative disease